glp-1 oral weight loss FDA approves Foundayo, an alternative to Wegovy and Ozempic 1 support with a 321% natural GLP FDA Approves New Weight Loss

Wang J, Song J, Song G, Feng Y, Pan J, Yang X, et al

In cardiovascular outcome trials of semaglutide in type 2 diabetes, rapid improvements in glycemic control were associated with an increased rate of diabetic retinopathy complications in high-risk patients, likely reflecting the well-known phenomenon of transient retinopathy worsening when glucose control improves quickly.9 More recently, observational analyses and pharmacovigilance reports have raised a possible association between semaglutide exposure and nonarteritic anterior ischemic optic neuropathy (NAION), leading to ongoing regulatory review

Pencek R, et al

The most frequent ones are nausea, constipation, diarrhea, burping, and low energy on injection days

Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes

2) Avoid:Strong acids (e.g., AHAs, high-dose vitamin C) or chelators (e.g., EDTA), which may destabilize the copper-peptide complex.